Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Novo Nordisk ( (NVO) ).
On January 20, 2025, Novo Nordisk announced the continuation of its share repurchase programme initiated on November 11, 2024, under the Safe Harbour Rules. The programme, part of a larger DKK 20 billion initiative set for a 12-month period starting February 6, 2024, aims to repurchase B shares up to DKK 3.14 billion by February 3, 2025. As of January 17, 2025, the company has repurchased 23,691,366 B shares at an average price of DKK 816.17, totaling DKK 19.34 billion. This repurchase strategy is critical for Novo Nordisk’s financial management and shareholder value enhancement, reflecting its robust financial positioning in the healthcare industry.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. It focuses on pioneering scientific breakthroughs to defeat serious chronic diseases, particularly in diabetes, by expanding access to medicines and working to prevent and cure diseases. The company employs about 72,000 people across 80 countries and markets its products in approximately 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange.
YTD Price Performance: -10.09%
Average Trading Volume: 7,392,360
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $339.8B
Find detailed analytics on NVO stock on TipRanks’ Stock Analysis page.
